Organization | University of San Francisco

University of San Francisco Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3

Organization Overview

First Clinical Trial

2016

NCT02563327

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

UCSF School of Medicine: UCSF Diabetes Clinic | University of San Francisco | University of San Francisco School of Pharmacy, San Francisco, CA

Active Ingredients

Drugs in Phase 3 Trials (9)

cetuximab (erbitux) (1 trial)

ethambutol (myambutol) (1 trial)

hafnium oxide (1 trial)

isoniazid (nydrazid) (1 trial)

moxifloxacin (avelox) (1 trial)

pyrazinamide (Aldinamide) (1 trial)

pyridoxine (1 trial)

rifampin (1 trial)

rifapentine (priftin) (1 trial)

Drugs in Phase 2 Trials (2)

enzalutamide (xtandi) (1 trial)

for46 (1 trial)

Drugs in Phase 1 Trials (1)

autologous regulatory t cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Pemphigus (Phase 1)

Tuberculosis (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 4
# of Trial APIs: 12